Xilio Therapeutics (XLO) Cash from Operations Growth (3y) (2023 - 2026)
Xilio Therapeutics (XLO) Cash from Operations Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Nanobiotix | 1,785.11 Bn | 1,785.05 Bn | - | - |
| 2 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 3 | BeOne Medicines | 473.57 Bn | 468.78 Bn | 1.35 Bn | 33.08% |
| 4 | Vertex Pharmaceuticals | 123.78 Bn | 116.54 Bn | 2.59 Bn | 16.64% |
| 5 | Regeneron Pharmaceuticals | 71.73 Bn | 62.98 Bn | 3.31 Bn | -7.60% |
| 6 | Belite Bio | 62.12 Bn | 62.12 Bn | - | - |
| 7 | Argenx Se | 54.64 Bn | 49.45 Bn | 1.41 Bn | - |
| 8 | Alnylam Pharmaceuticals | 38.05 Bn | 35.05 Bn | 959.66 Mn | 34.32% |
| 9 | Revolution Medicines | 36.28 Bn | 36.28 Bn | - | - |
| 10 | Xilio Therapeutics | 148.07 Mn | -2.23 Mn | - | 4.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.00% |
| Dec 31, 2025 | 52.14% |
| Sep 30, 2025 | 4.22% |
| Jun 30, 2025 | 4.76% |
| Mar 31, 2025 | 50.23% |
| Dec 31, 2024 | 6.21% |
| Sep 30, 2024 | 12.94% |
| Jun 30, 2024 | 44.08% |
| Mar 31, 2024 | 22.70% |
| Dec 31, 2023 | -1.86% |